| Current Price | $155.30 | Mkt Cap | $7.6B |
|---|---|---|---|
| Open | $157.17 | P/E Ratio | 32.48 |
| Prev. Close | $155.30 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $154.77 - $157.27 | Volume | 89,472 |
| 52-Wk Range | $150.73 - $161.22 | Avg. Daily Vol. | 305,760 |
The Company is a global provider of solutions that advance the drug discovery and development process. It provides the animal research models required in research and development for new drugs, devices and therapies.
| Current Price | $155.30 | Mkt Cap | $7.6B |
|---|---|---|---|
| Open | $157.17 | P/E Ratio | 32.48 |
| Prev. Close | $155.30 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $154.77 - $157.27 | Volume | 89,472 |
| 52-Wk Range | $150.73 - $161.22 | Avg. Daily Vol. | 305,760 |
Read the most recent pitches from players about CRL.
Recs
MaestroFool
(87.66)
Submitted: 12/15/2019 4:28:09 PM :
Start Price:
$123.48
NYSE:CRL Score:
+12.32
Charles River breeds and sells lab rats, mice, bunnies, guinea pigs of all shapes and sizes and in various states of sickness, health, obesity, and even already having had various clinical procedures and operations. This company's work is unpleasant, but essential for the clinical trials and research behind the groundbreaking treatments and therapies that allow us to live longer and healthier.
Recs
kenjotto
(< 20)
Submitted: 8/10/2011 10:16:21 AM :
Start Price:
$30.59
NYSE:CRL Score:
+216.51
Activist inspired turn around is progressing well. They're repurchasing shares, cutting underperforming segments, and increasing and improving their sales to key end users. As big pharma looks to revive its pipeline, they'll come to CRL. Plus, CRL is only #2 in the CRO industry, so they have runway ahead of them!
Recs
fdude71
(< 20)
Submitted: 12/29/2010 7:36:40 AM :
Start Price:
$35.57
NYSE:CRL Score:
+175.59
Bought RL at $35.57.
CRL is the dominant provider of lab rats (moat) and provides "research outsourcing" to the "Big Pharmas" (double the moat if you consider the tight relationship needed to get contracts in this field).
This is a cyclical business... at -or near- the bottom of the weakness cycle.
Recent stock buybacks.
A group of activist investors owns 15% of CRL.
I expect this to be a very profitable play, though there will be bumps along the ride - snag this around $30/piece if you can- given the fairly high valuation of the business.
Find the members with the highest scoring picks in CRL.
tskephart (94.35) Score: +323.81
The Score Leader is the player with the highest score across all their picks in CRL.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| tskephart | 94.35 | 11/26/2008 |
|
3Y | $21.87 | +610.11% | +286.29% | +323.81 | 1 Comment | |
| dingo72 | 84.23 | 12/3/2008 |
|
3Y | $21.94 | +607.84% | +292.37% | +315.47 | 0 Comment | |
| 5st4 | 66.63 | 1/9/2009 |
|
NS | $23.91 | +549.52% | +267.09% | +282.43 | 0 Comment | |
| DFT2007 | 99.83 | 11/17/2008 |
|
NS | $23.35 | +565.10% | +290.54% | +274.56 | 0 Comment | |
| jackjjr | 83.23 | 11/17/2011 |
|
5Y | $28.96 | +436.26% | +166.83% | +269.42 | 0 Comment | |
| dog1350 | 68.16 | 12/11/2008 |
|
5Y | $24.17 | +542.53% | +276.74% | +265.79 | 0 Comment | |
| kagold | 84.51 | 10/4/2011 |
|
5Y | $27.68 | +461.05% | +203.48% | +257.58 | 0 Comment | |
| elzbal | 31.90 | 10/17/2011 |
|
1Y | $29.43 | +427.69% | +171.57% | +256.12 | 0 Comment | |
| JohnGabriel | 86.66 | 9/29/2011 |
|
5Y | $28.97 | +436.07% | +183.73% | +252.34 | 0 Comment | |
| CMFGouldberg | 77.82 | 10/3/2011 |
|
5Y | $28.18 | +451.10% | +199.12% | +251.98 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
